Cognivue to conduct national study on cognitive assessment systems
Click Here to Manage Email Alerts
Cognivue, a neuroscience company, announced it will launch a national study to differentiate the effectiveness of its cognitive assessment systems.
The study is intended to confirm Cognivue’s total scoring, age-specific normative ranges, test-retest reliability, training effect, sensitivity and specificity, compared with other frequently used paper and digital cognitive screening tests, the company announced in a press release. James E. Galvin, MD, MPH, professor of neurology, psychiatry and behavioral sciences at the University of Miami Miller School of Medicine, and colleagues will conduct the study of 2,000 participants in up to 14 cities.
“The investments that Cognivue is making for studies like [this] have critical importance for further verifying and developing the company’s technology and ultimately improving outcomes for patients,” Galvin said in the release. “I am very pleased to be a part of this study as lead investigator.”
The study will consist of two arms: one for Cognivue’s 10-minute self-administered computerized assessment based on the company’s FDA-cleared technology; the other for Cognivue’s 5-minute self-administered computerized screening of cognitive function.
The first trial participant is expected to begin the study in August, with completion approximately 5 months later.